Physician profile
Russell D Briggs
NPI 1942245196
$8,748.75
in general payments reported to CMS, 2019-2025
26 companies · $2,578 in 2025
The $2,578 reported for 2025 was more than what 92% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $315 · 2021: $965 · 2022: $1,397 · 2023: $1,613 · 2024: $1,194 · 2025: $2,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,190 · Consulting Fee: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,190.44 |
| Consulting Fee | $195.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,777.26 | 2021-2025 | Inspire |
| Genzyme Corporation | $1,378.23 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,317.15 | 2019-2025 | Dupixent |
| Optinose US, INC. | $660.20 | 2019-2025 | |
| Stryker Corporation | $592.98 | 2019-2024 | Scopis Ent |
| Acclarent, INC | $450.60 | 2019-2022 | |
| Glaxosmithkline, LLC. | $415.83 | 2021-2025 | Nucala, Trelegy Ellipta |
| Aerin Medical INC. | $404.70 | 2020-2025 | |
| Medtronic, INC. | $401.11 | 2021-2024 | Straightshot, Nuvent, Merocel |
| Carestream Dental, LLC | $372.79 | 2022 | |
| Integra Lifesciences Corporation | $367.37 | 2024-2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Abbvie INC. | $144.46 | 2022-2023 | Vraylar |
| Hikma Pharmaceuticals USA | $73.29 | 2022-2025 | Ryaltris |
| Itamar Medical INC | $60.67 | 2022-2023 | Watchpatone |
| Astrazeneca Pharmaceuticals Lp | $59.18 | 2022-2025 | Tezspire |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $47.63 | 2022 | |
| Greer Laboratories, INC. | $42.87 | 2023-2025 | Oralair |
| Lilly USA, LLC | $35.91 | 2025 | Mounjaro, Zepbound |
| Pfizer INC. | $28.44 | 2023-2024 | |
| Ars Pharmaceuticals Operations, INC. | $22.83 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $21.53 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.63 | 2025 | Xhance |
| Olympus America INC. | $16.76 | 2022 | |
| Medtronic USA, INC. | $15.53 | 2020 | |
| Xoran Technologies LLC | $11.50 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Briggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.